ALMS_OUT_1 [2025-04-04 09:53:33 -0400] 3649 Bytes | 1056 tokens | Cum: 1056 tkns (13.20% of 8k)
==========================================================================

We're scouting for winners today. Its 9:53:32 AM on Fri Apr 04, 2025 -0400 and I'm looking at Alumis (ALMS) up to 9.8131 from 8.54

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Alumis (ALMS)
IPO: 2024-06-28 (9 Months Ago)
Market Cap: $393,909,047
Shares Outstanding: 47,220,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

Here’s the first list of news for Alumis:

C1 - Mar-25-25 10:51AM - Alumis and Kaken sign agreement in Japan to develop ESK-001
C2 - Mar-25-25 10:51AM 02:30AM - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
C3 - Mar-21-25 07:08AM - Why Alumis Inc. (ALMS) Went Down On Thursday?
C4 - Mar-19-25 04:05PM - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
C5 - Mar-10-25 08:00AM - Alumis to Present at Leerink's 2025 Global Healthcare Conference
C6 - Mar-08-25 09:00AM - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
C7 - Mar-04-25 09:01AM - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
C8 - Mar-04-25 09:01AM 09:01AM - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Prior AI Reports for ALMS:
1. 2025-04-02 – Score: 50 – Target: 9.2400 – Highs: 10.4200 / 9.7000 / –
companys-high-trading-volume-amid-negative-returns-raises-questions
2. 2025-04-01 – Score: 45 – Target: 10.6600 – Highs: 7.2500 / 10.4200 / 9.70
high-volume-sparks-hope-despite-bleak-financial-indicators
3. 2025-03-26 – Score: 45 – Target: 5.3000 – Highs: 6.0400 / 5.0500 / 6.00
increased-market-interest-amidst-financial-distress-a-closer-look
4. 2025-03-25 – Score: 30 – Target: 6.1900 – Highs: 5.7000 / 6.0400 / 5.05
alumis-inc-faces-downward-market-trend-amid-zero-revenue

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Alumis (ALMS).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

ALMS_OUT_3 [2025-04-04 09:53:41 -0400] 1109 Bytes | 324 tokens | Cum: 1383 tkns (17.29% of 8k)
==========================================================================

Showing C4 (chunk 1 of 19): C4:
**Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements**
Date: Mar-19-25 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/19/3045800/0/en/Alumis-Reports-Year-End-2024-Financial-Results-and-Highlights-Recent-Achievements.html

March 19, 2025 16:05 ET| Source:Alumis Inc.Alumis Inc.

– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 –

– Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 –

– Announced merger agreement with ACELYRIN to create combined company with differ

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALMS_OUT_5 [2025-04-04 09:53:42 -0400] 949 Bytes | 294 tokens | Cum: 1853 tkns (23.16% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T09:53:37Z - Alumis Inc. (NASDAQ:ALMS) CEO Acquires $100,786.00 in Stock...
A2 - 2025-04-03T22:06:49Z - Alumis Inc. director Alan Colowick buys $129,544 in stock By Investing.com...
A3 - 2025-04-03T22:06:44Z - Alumis Inc. CEO Martin Babler buys $100,732 in company stock By Investing.com...
A4 - 2025-04-02T17:06:16Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Allakos (NASDAQ:ALLK), Alumis (NASDAQ...
A5 - 2025-04-01T14:32:43Z - Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On T...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ALMS_OUT_7 [2025-04-04 09:53:46 -0400] 1098 Bytes | 321 tokens | Cum: 2176 tkns (27.20% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Alumis Inc. (NASDAQ:ALMS) CEO Acquires $100,786.00 in Stock**Date: 2025-04-04Source: {'uri': 'insidertrades.com', 'dataType': 'news', 'title': 'InsiderTrades.com'}URL: https://www.insidertrades.com/alerts/nasdaq-alms-insider-buying-and-selling-2025-04-04/Alumis Inc. (NASDAQ:ALMS - Get Free Report) CEO Martin Babler acquired 15,650 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was bought at an average cost of $6.44 per share, with a total value of $100,786.00. Following the completion of the transaction, the chief executive officer now directly owns 106,454 shares in the company, valued at $685,563.76. The trade was a 17.23 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of ALMS stock opened at $8.54 on

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALMS_OUT_9 [2025-04-04 09:53:47 -0400] 1096 Bytes | 341 tokens | Cum: 2612 tkns (32.65% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-19T20:05:00Z - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
B2 - 2025-03-13T17:52:00Z - Metal-Organic Frameworks Market to Reach $949.2 Million by 2029, Growing at 15.6% CAGR
B3 - 2025-03-08T14:00:00Z - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
B4 - 2025-03-04T14:01:00Z - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
B5 - 2025-03-04T14:01:00Z - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
B6 - 2025-02-06T21:15:00Z - Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALMS_OUT_11 [2025-04-04 09:53:50 -0400] 759 Bytes | 196 tokens | Cum: 2810 tkns (35.12% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/03/g44405196/alumis-reports-year-end-2024-financial-results-and-highlights-recent-achievementsAlumis reported strong 2024 results, with progress on its late-stage pipeline of oral TYK2 inhibitors for immune-mediated diseases. The company also announced a merger agreement with ACELYRIN to create a combined company with a differentiated portfolio and increased financial flexibility.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALMS_OUT_13 [2025-04-04 09:53:51 -0400] 1085 Bytes | 285 tokens | Cum: 3169 tkns (39.61% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S3 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99....

S4 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99....

S5 - 2025-03-19 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and the related note...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALMS_OUT_15 [2025-04-04 09:53:58 -0400] 1003 Bytes | 260 tokens | Cum: 3431 tkns (42.89% of 8k)
==========================================================================

Showing S3 (chunk 1 of 1): S3:
Item 2.02 Results of Operations and Financial Condition.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALMS_OUT_17 [2025-04-04 09:54:09 -0400] 5104 Bytes | 1410 tokens | Cum: 4975 tkns (62.19% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+------------------------+-----------------------+
| Volume: 111,605 | Perf Month: 90.33% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+----------------------+------------------------+-----------------------+
| Avg Volume: 620.40K | Perf Quarter: 18.09% | Short Float: 12.08% | ROE: -198.66% |
+---------------------+----------------------+------------------------+-----------------------+
| Rel Volume: 2.59 | Index: RUT | Short Ratio: 4.92 | ROI: -101.72% |
+---------------------+----------------------+------------------------+-----------------------+
| RSI (14): 72.99 | Market Cap: 528.12M | Short Interest: 3.05M | Sales Surprise: - |
+---------------------+----------------------+------------------------+-----------------------+
| ATR (14): 1.13 | Shs Outstand: 47.22M | Beta: - | EPS Surprise: -24.94% |
+---------------------+----------------------+------------------------+-----------------------+
| SMA20: 78.43% | Shs Float: 25.25M | Sales Q/Q: - | P/E: - |
+---------------------+----------------------+------------------------+-----------------------+
| SMA50: 75.03% | Inst Own: 34.73% | Sales past 5Y: 0.00% | Earnings: Mar 19 AMC |
+---------------------+----------------------+------------------------+-----------------------+
| SMA200: 3.20% | Insider Own: 53.59% | Employees: 168 | |
+---------------------+----------------------+------------------------+-----------------------+
| Perf Week: 72.11% | Insider Trans: 0.12% | Debt/Eq: 0.12 | |
+---------------------+----------------------+------------------------+-----------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: ALUMIS INC. (ALMS) by Colowick Alan (Unknown Title) on 2025-04-01
- Common Stock: 16104 shares at $6.974 (I)
- Common Stock: 2300 shares at $7.4935 (I)

Inside Trans: ALUMIS INC. (ALMS) by Babler Martin (President, CEO and Chairman) on 2025-04-01
- Common Stock: 15650 shares at $6.4366 (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -294233000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.89
Average Volume: 1278009.43
30-Day High: 9.89
30-Day Low: 3.57

[Detailed Financials: TTM 2024]
- Total Assets: $340,992,000.0
- Total Liabilities: $80,888,000.0
- Total Equity: $260,104,000.0
- Current Assets: $306,188,000.0
- Current Liabilities: $50,910,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.38

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $123,499,000.0

[Detailed Financials: FY 2024]
- Total Assets: $340,992,000.0
- Total Liabilities: $80,888,000.0
- Total Equity: $260,104,000.0
- Current Assets: $306,188,000.0
- Current Liabilities: $50,910,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.38

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $123,499,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

ALMS_OUT_19 [2025-04-04 09:54:13 -0400] 687 Bytes | 169 tokens | Cum: 5381 tkns (67.26% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

ALMS_IN_21 [2025-04-04 09:54:13 -0400] 126 Bytes | 29 tokens | Cum: 5481 tkns (68.51% of 8k)
==========================================================================

====================================
[2025-04-04 09:54:13] # Analysis Completed
Elapsed Time: 41.52 seconds